Drupal.behaviors.print = function(context) {window.print();window.close();}>
Epigenomics Licenses Septin9 Biomarker to Companion Dx Lab for Colorectal Cancer Test
June 19, 2012
Epigenomics Licenses Septin9 Biomarker to Companion Dx Lab for Colorectal Cancer Test
By
a GenomeWeb staff reporter
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
BioChain Licenses Epigenomics Methylation Marker
March 7, 2013 / GenomeWeb Daily News
Qiagen Expands Companion Dx Portfolio with Three Licensing Deals; Exceeds 2012 QiaSymphony Placement Target
January 7, 2013 / GenomeWeb Daily News
Warnex Licenses Rights to Cancer Dx Technology from Epigenomics
May 3, 2010 / GenomeWeb Daily News
Trovagene, PerkinElmer Ink Assay Development Deal Targeting Liver Cancer
April 26, 2013 / GenomeWeb Daily News
Epigenomics' FDA Application for Cancer Test to Get FDA Priority Review
February 21, 2013 / GenomeWeb Daily News